Lipolytic effect of using liraglutide in individuals with obesity and type 2 diabetes

• Grant number: 24/15480-2
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2024
• End date: September 30, 2025
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Licio Augusto Velloso
• Grantee: Doriel Ferreira de Jesus Alves
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Associated research grant: 13/07607-8 - OCRC - Obesity and Comorbidities Research Center, AP.CEPID

Abstract

Obesity is currently one of the most prevalent diseases on the planet. Unfortunately, behavioral approaches, which include increasing physical activity combined with reducing caloric intake, have a high rate of refractoriness, and in general, patients are unable to adhere to the recommendations for long periods. In the last decade, the introduction of glucagon-like peptide-1 receptor agonists (GLP-1) has been a major therapeutic advancement that has contributed to very satisfactory results in disease control. Clinical and experimental studies suggest that medications in this class primarily act by reducing caloric intake; however, little is known about the lipolytic effect resulting from the use of these medications. In this project, we will conduct a systematic review with the aim of advancing the understanding of the lipolytic effect of liraglutide, the first medication in this class approved for the treatment of obesity.